Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study.

The relationship among insulin resistance, adiponectin, and cardiovascular (CV) morbidity in patients with mild and moderate kidney disease was investigated. Insulin sensitivity (Homeostasis Model Assessment of Insulin Resistance [HOMA-IR]) and adiponectin plasma levels were assessed in 227 nondiabetic renal patients at different degrees of renal dysfunction and in 76 healthy subjects of similar age and gender distribution and body mass index. In renal patients, association with prevalent CV events was evaluated, and incident CV events were evaluated in a prospective study. HOMA-IR was markedly higher in patients than in healthy subjects (3.59 +/- 3.55 versus 1.39 +/- 0.51; P < 0.01). In renal patients, HOMA-IR was significantly correlated with body mass index (r = 0.477; P < 0.01), triglycerides (r = 0.384; P < 0.01), adiponectin plasma levels (r = -0.253; P < 0.01), and age (r = 0.164; P < 0.05), but not with renal function (GFR by iod-thalamate clearance). Patients with previous CV events were significantly older, had higher HOMA-IR and serum triglycerides, and had lower adiponectin plasma levels (all P < 0.05). Logistic regression analysis revealed age (P < 0.001) and adiponectin (P < 0.002) as independent variables related to prevalent CV events. In the prospective study, median follow-up was 54 mo. Patients who experienced CV events had significantly higher serum glucose and lower adiponectin plasma levels (both P < 0.05). In patients with chronic kidney diseases, a syndrome of insulin resistance is present even in the earliest stage of renal dysfunction, and several components of this syndrome are associated with CV events. Moreover, hypoadiponectinemia is a novel putative CV risk factor in patients with mild and moderate renal failure.

[1]  G. Pacini,et al.  Intravenous calcitriol normalizes insulin sensitivity in uremic patients. , 1995, Kidney international.

[2]  F. Kronenberg,et al.  Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. , 2002, Journal of the American Society of Nephrology : JASN.

[3]  J. Kastelein,et al.  New Risk Factors for Atherosclerosis and Patient Risk Assessment , 2004, Circulation.

[4]  V. Mazzaferro,et al.  Nonhepatic glucose production in humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[5]  M. Woodward,et al.  Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 000 participants. , 2004, International journal of epidemiology.

[6]  E. Ritz,et al.  Altered temporal organization of plasma insulin oscillations in chronic renal failure. , 2002, The Journal of clinical endocrinology and metabolism.

[7]  A. Xu,et al.  Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. , 2004, The Journal of clinical endocrinology and metabolism.

[8]  J. Alroy,et al.  Renal pathology in Fabry disease. , 2002, Journal of the American Society of Nephrology : JASN.

[9]  T. Saruta,et al.  Mild renal dysfunction is associated with insulin resistance in chronic glomerulonephritis. , 2000, Clinical nephrology.

[10]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[11]  M. Stumvoll,et al.  Renal substrate exchange and gluconeogenesis in normal postabsorptive humans. , 2002, American journal of physiology. Endocrinology and metabolism.

[12]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[13]  N. Perico,et al.  Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. , 1998, Journal of the American Society of Nephrology : JASN.

[14]  H. Koyama,et al.  Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[15]  S. Kihara,et al.  Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. , 2003, Kidney international. Supplement.

[16]  K. Woo,et al.  Deleterious Impact of “High Normal” Glucose Levels and Other Metabolic Syndrome Components on Arterial Endothelial Function and Intima-Media Thickness in Apparently Healthy Chinese Subjects: The CATHAY Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[17]  R. Wilkinson,et al.  Insulin resistance in adult polycystic kidney disease. , 1997, Kidney international.

[18]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[19]  P. Stenvinkel,et al.  Renal hemodynamics and sodium handling in moderate renal insufficiency: the role of insulin resistance and dyslipidemia. , 1995, Journal of the American Society of Nephrology : JASN.

[20]  S. Spaia,et al.  Effect of Short-Term rHuEPO Treatment on Insulin Resistance in Haemodialysis Patients , 2000, Nephron.

[21]  S. Kihara,et al.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[22]  S. Strandgaard,et al.  Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity , 1995, Diabetologia.

[23]  M. Stumvoll,et al.  Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. , 1995, The Journal of clinical investigation.

[24]  B. Goldstein,et al.  Adiponectin: A novel adipokine linking adipocytes and vascular function. , 2004, The Journal of clinical endocrinology and metabolism.

[25]  G. Pacini,et al.  Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. , 1998, Kidney international.

[26]  P. Whelton,et al.  Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. , 2003, Journal of the American Society of Nephrology : JASN.

[27]  P. Garlick,et al.  Insulin regulation of renal glucose metabolism in humans. , 1999, American journal of physiology. Endocrinology and metabolism.

[28]  Cynthia J. Girman,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[29]  R. Schall,et al.  Old antihypertensives and new diabetes , 2004, Journal of hypertension.

[30]  P. Stenvinkel,et al.  Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. , 2004, Kidney international.

[31]  E. Ritz,et al.  Increased genetic risk of hypertension in glomerulonephritis? , 1990, Journal of hypertension.

[32]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[33]  R. DeFronzo,et al.  Insulin resistance in uremia. , 1981, The Journal of clinical investigation.

[34]  S. Haffner,et al.  Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. , 2002, Diabetes care.

[35]  E. Bonora,et al.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.

[36]  M. Reilly,et al.  The Metabolic Syndrome: More Than the Sum of Its Parts? , 2003, Circulation.

[37]  A. Alvestrand Carbohydrate and insulin metabolism in renal failure. , 1997, Kidney international. Supplement.

[38]  E. Lonn,et al.  Cardiovascular risk in patients with mild renal insufficiency. , 2003, Kidney international. Supplement.

[39]  W. Guder,et al.  Renal substrate metabolism. , 1986, Physiological reviews.